Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

We developed a model of chorioamnionitis to simulate fetal exposure to maternal inflammation (FEMI) without complications of live organisms to examine the effects of FEMI on development of the offspring’s intestinal tract. This allows for study of mechanistic causes for development of intestinal injury following chorioamnionitis.

Abstract

Chorioamnionitis is a common precipitant of preterm birth and is associated with many of the morbidities of prematurity, including necrotizing enterocolitis (NEC). However, a mechanistic link between these two conditions remains yet to be discovered. We have adopted a murine model of chorioamnionitis involving lipopolysaccharide (LPS)-induced fetal exposure to maternal inflammation (FEMI). This model of FEMI induces a sterile maternal, placental, and fetal inflammatory cascade, which is also present in many cases of clinical chorioamnionitis. Although models exist that utilize live bacteria and more accurately mimic the pathophysiology of an ascending infection resulting in chorioamnionitis, these methods may cause indirect effects on development of the immature intestinal tract and the associated developing microbiome. Using this protocol, we have demonstrated that LPS-induced FEMI results in a dose-dependent increase in pregnancy loss and preterm birth, as well as disruption of normal intestinal development in offspring. Further, we have demonstrated that FEMI significantly increases intestinal injury and serum cytokines in offspring, while simultaneously decreasing goblet and Paneth cells, both of which provide a first line of innate immunity against intestinal inflammation. Although a similar model of LPS-induced FEMI has been used to model the association between chorioamnionitis and subsequent abnormalities of the central nervous system, to our knowledge, this protocol is the first to attempt to elucidate a mechanistic link between chorioamnionitis and later perturbations in intestinal development as a potential link between chorioamnionitis and NEC.

Introduction

The chorionic membranes play an integral role in mammalian pregnancy. They include the chorion and amnion, which serve multiple functions. They surround and protect the fetus, facilitate paracrine signaling between the maternal and fetal compartments1, and create local feedback loops within the chorionic membranes, which may be involved in initiating parturition1. Current understanding of the membranes indicates that the amnion provides structural barrier function, and the chorion provides an immunological buffer primarily to protect the developing fetus from the maternal immune system2. Inflammation of these membranes is known as chorioamnionitis. Historically, the diagnosis of clinical chorioamnionitis was made following the presence of maternal fever plus one or more fetal or maternal clinical findings3,4. However, while this definition is clinically useful, its lack of precision has made chorioamnionitis research challenging. In 2015, in an attempt to clarify the diagnosis, an expert panel workshop by the Eunice Kennedy Shriver National Institute for Child Health and Human Development defined chorioamnionitis as intrauterine inflammation, or infection, or both (triple I)3. This clarification is important because while microbial induced infection is an important cause of uterine/amniotic inflammation, it occurs less commonly than sterile uterine/amniotic inflammation5,6,7. Overall, chorioamnionitis remains a significant public health problem, as it is seen in 2‒4% of term deliveries and 25‒30% of preterm deliveries8,9.

Chorioamnionitis can have significant effects on the fetus and neonate. It has been well documented in the literature that chorioamnionitis is associated with increased risk of many of the morbidities of prematurity, including bronchopulmonary dysplasia10, cerebral white matter injury11, intraventricular hemorrhage12, retinopathy of prematurity13, and both suspected and confirmed early onset neonatal sepsis14,15. As we are interested in injury and repair mechanisms of the immature intestinal tract, it is important to note that chorioamnionitis is also associated with later development of necrotizing enterocolitis (NEC)15,16. NEC is a devastating gastrointestinal disease of preterm infants that results in a dysregulated host response to inflammation and subsequent intestinal necrosis17. Each year, NEC affects over 4000 infants in the United States, and up to one third of these infants die from the disease18. The pathogenesis of NEC likely involves a combination of intestinal immaturity, dysregulation of the immature immune system, intestinal inflammation, and bacterial translocation19, culminating in a final common pathway of intestinal necrosis. Importantly, the onset of NEC often occurs weeks after birth and potential exposure to chorioamnionitis, making the mechanistic link between chorioamnionitis and subsequent development of NEC unclear20. One potential mechanism by which chorioamnionitis may contribute to the pathophysiology of NEC is through upregulation of the maternal immune system, subsequently producing a strong fetal inflammatory response which may disrupt normal fetal developmental patterns21,22,23.

Multiple mammalian models of chorioamnionitis exist in rodents and sheep24,25,26,27,28,29,30,31,32. However, few data exist concerning the development of the intestinal tract beyond the initial newborn period following chorioamnionitis-induced fetal exposure to maternal inflammation (FEMI). In order to explore the relationship between FEMI and subsequent development of injury of the immature intestinal tract, we have adapted the lipopolysaccharide (LPS)-induced FEMI model. Lipopolysaccharides are a major component of the extracellular surface on gram negative bacteria and are a potent stimulant of the innate immune system of multiple eukaryotic species, including humans33. Maternal LPS injection results in a sterile inflammatory cascade without the confounding effects of live bacteria, and it is a well-established model for induction of preterm birth34, as well as a model of acute chorioamnionitis and the fetal inflammatory response syndrome (FIRS), which is the most severe form of chorioamnionitis24,35. It has also been shown to induce both cerebral white and gray matter injury in a sheep model36 and a murine model37,38,39,40. However, to our knowledge, we are the first to use this model of chorioamnionitis and FEMI to investigate its effects on the development of the gastrointestinal tract past birth, as well as to investigate a possible mechanistic link between chorioamnionitis and later development of NEC41,42.

Protocol

All animal procedures were approved by the University of Iowa Institutional Animal Care and Use Committee (Protocol #8041401). All animals were housed in an Association for Assessment and Accreditation of Laboratory Animal Care (AALAC) approved vivarium at the University of Iowa. All mice were wild type strain C57Bl/6J.

1. Establishment of FEMI in pregnant mice

  1. LPS preparation
    1. Use LPS derived from Escherichia coli O55:B5 (stock concentration 2 mg/mL).
    2. Dilute LPS stock concentration 1:100 with sterile saline for a working concentration of 20 µg/mL.
  2. Maternal LPS injection
    1. Inject pregnant dams at gestation day e15. This timepoint is approximately 75% through the murine pregnancy, making this model developmentally similar to the early third trimester of human pregnancies, which is when the majority of preterm births due to chorioamnionitis occur.
    2. Weigh pregnant mice immediately prior to injection to determine appropriate LPS dosing.
    3. Calculate the dose of working concentration by using the following formula: 5 µL x gram body weight (gbw), for a total dose of LPS of 100 µg/kg. For control animals, use an equivalent volume of normal saline for injection.
    4. Vortex LPS solution three times for 15 seconds on high prior to each injection.
    5. Draw up LPS volume into a 1 mL syringe.
    6. Restrain pregnant mouse with scruffing technique. Hold in dorsal recumbency position and perform the injection.
      1. Insert a 30 gauge 8 mm needle bevel up overlying the right lower quadrant of the abdomen (to avoid bladder and abdominal vessels) at a 30‒40° angle. Insert about ¼ to ½ the length of the needle.
      2. Pull back on the syringe plunger to ensure negative pressure prior to injecting. Proceed with injection if negative pressure is present.
      3. Following injection, monitor mice for approximately 30 min and then return to cages for the remainder of the pregnancy.

2. Delivery and care of offspring, and intestinal harvesting

  1. Deliver pups normally via vaginal delivery at e20.
    NOTE: This model does have an expected dose-dependent fetal loss rate that can be seen in Figure 1 and is discussed in the results below.
  2. Allow pups to remain with mothers and receive ad libitum feeds.
  3. On the day of harvest, typically postnatal day 14 (P14), euthanize pups via cervical dislocation in compliance with Institutional Animal Care and Use Committee protocols.
  4. Using scissors and forceps, make a vertical incision down the midline of the abdomen, through the skin and peritoneum, for the entire length of the abdomen. Excise the small intestine from the stomach to the cecum with scissors and remove the mesentery with forceps. 
  5. Isolate and keep the distal 1/3 of the small intestine (section representative of human ileum), discarding the proximal small intestine, the cecum, and the colon.
  6. Divide the ileum portion in half using scissors.
  7. Place the proximal half in an RNA stabilization solution for later RNA quantification.
  8. Place the distal half in 10% neutral buffered formalin for slide preparation.

3. Intestinal injury scoring

  1. Section paraffin embedded tissue into 5 µm thick slices and mount on glass slides.

    NOTE: We send the specimens to a histology core for paraffin embedding, sectioning, and mounting onto slides.
  2. Deparaffinize slides according to standard procedures.
  3. Stain sections with hematoxylin and eosin according to standard procedures.
  4. Score sections on a 3-point scale for intestinal injury as previously described42,43.
    1. Using light microscopy, assess generalized intestinal injury by two separate blinded investigators on a 3-point scale evaluating villus integrity and separation from the basement membrane43 (Supplementary Figure 1). Intestinal injury is best assessed at 20x magnification and numerical aperture 0.50.
    2. Assign a score of 0 to describe normal mucosa.
    3. Assign a score of 1 describe mild injury which encompasses the development of subepithelial Gruenhagen’s space, vacuolization or subepithelial lifting limited to the lamina propria or tips of villi.
    4. Assign a score of 2 to describe severe injury, indicated by epithelial lifting and vacuolization greater than half of the villi, villi distortion, or mucosal ulceration and disintegration of the lamina propria.

4. Quantification of Paneth and goblet cells

  1. Following deparaffinization, stain slides of tissue sections from Step 2.8 with Alcian Blue/Periodic Acid Schiff stain to denote both goblet and Paneth cells as previously described44,45 according to the following steps.
    NOTE: While Alcian Blue/Periodic Acid Schiff stain is not specific to either Paneth or goblet cells, in our experience, blinded experienced investigators have equivalent cellular quantification using this stain compared to cellular targeted antibodies, with significantly less background staining46.
  2. Deparaffinize, stain, and dehydrate slides as follows.
    1. Submerge slides in xylene for 10 min twice.
      CAUTION: Xylene should be used in a fume hood.
    2. Rinse with 100% EtOH.
    3. Submerge slides in 100 % EtOH for 3 min, then in 90% EtOH for 3 min, followed by 70% EtOH for 3 min, and lastly submerge slides in 50% EtOH for 3 min.
    4. Wash under running tap water for 5 min.
      CAUTION: Point the section away from the running water to prevent loss of tissue sample.
    5. Filter Alcian blue stain solution with a standard coffee filter.
    6. Stain slides in Alcian blue stain for 15 min and then wash under running tap water for 2 min.
    7. Dilute 1 mg of periodic acid in 200 mL of double distilled water. Submerge slides in this solution for 5 min. Then wash under running tap water for 1 min.
    8. Stain with Schiff’s reagent for 10 min. Wash under running tap water for 5 min.
    9. Stain the slides with hematoxylin for 1 min and then wash under running tap water for 2 min.
    10. Submerge them in acid alcohol (1 mL of hydrochloric acid mixed in 99 mL of 70% EtOH) for 1 min.
    11. Submerge in Scott’s tap water (0.1% concentration of NaHCO3 in tap water) for 1 min and then wash under running tap water for 1 min.
    12. Dehydrate the slides.
      1. Dip each slide 10 times in 70% EtOH, then dip 10 times in 90% EtOH, and 10 times in 100% EtOH.
      2. Submerge slides in 100% EtOH for 10 min, followed by submerging twice in fresh xylene for 3 min each.
    13. Place a drop of mounting media on the specimen and place a coverslip over it.
  3. Goblet cell counting
    1. Using light microscopy, count goblet cells (Supplementary Figure 2). For each piece of intestinal tissue, count the number of goblet cells and 500 epithelial cells and express goblet cell ratio as a ratio per 100 epithelial cells. Goblet cells are best counted at 20x magnification and numerical aperture 0.5.
  4. Paneth cell counting
    1. Using light microscopy, count Paneth cells (Supplementary Figure 2). For each piece of intestinal tissue, express as a ratio of Paneth cells per intestinal crypt. Count 100 intestinal crypts per each piece of intestinal tissue. Paneth cells are best counted at 20x-60x magnification and numerical aperture 0.50-1.30.

Results

Exposure to FEMI on embryonic day 15 leads to a dose-dependent loss of pregnancy and a dose dependent rate of preterm labor (Figure 1)42. For the experiments, we chose to use an LPS dose of 100 µg/kg to minimize pregnancy loss and prematurity (50% loss between both prematurity and intrauterine fetal demise) while exposing the fetuses to a significant inflammatory insult.

Using this approach, we next examined the effects of FEMI on subs...

Discussion

Chorioamnionitis impacts 2‒4% of term and 25‒30% of preterm deliveries8,9. However, the impact of chorioamnionitis can extend long past birth as it has been shown to have significant effects on the fetus and neonate10,11,12,13,14,15,

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported in part through the National Institutes of Health (DK097335 & T32AI007260) and the University of Iowa Stead Family Department of Pediatrics.

Materials

NameCompanyCatalog NumberComments
10% neutral buffered formalinSigmaHT501128
Alcian blue stainNewcomer supply1003A
C57Bl6/J miceJackson Laboratories664
EthanolDecon labs2701
HClSigmaH1758
Hematoxylin stainLeica381562
LPSSigmaL2880
NaHCO3SigmaS6014
Nikon Eclipse Ni-U MicroscopeNikon2CE-MQVJ-1
Periodic AcidACROSH5106CAS# 10450-59-9
RNAlaterThermofisherAm7021
Schiff's reagentSigmaS5133
Secor Imager 2400Meso Scale Discovery (MSD)
V-Plex AssayMeso Scale Discovery (MSD)
XyleneSigma534056

References

  1. Myatt, L., Sun, K. Role of fetal membranes in signaling of fetal maturation and parturition. International Journal of Developmental Biology. 54 (2-3), 545-553 (2010).
  2. Verbruggen, S. W., Oyen, M. L., Phillips, A. T., Nowlan, N. C. Function and failure of the fetal membrane: Modelling the mechanics of the chorion and amnion. PLoS One. 12 (3), 0171588 (2017).
  3. Higgins, R. D., et al. Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop. Obstetrics & Gynecology. 127 (3), 426-436 (2016).
  4. Peng, C. C., Chang, J. H., Lin, H. Y., Cheng, P. J., Su, B. H. Intrauterine inflammation, infection, or both (Triple I): A new concept for chorioamnionitis. Pediatrics and Neonatology. 59 (3), 231-237 (2018).
  5. Romero, R., et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. American Journal of Reproductive Immunology. 72 (5), 458-474 (2014).
  6. Romero, R., et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. Journal of Maternal-Fetal and Neonatal. , 1-17 (2014).
  7. Romero, R., et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. Journal of Maternal-Fetal and Neonatal Medicine. 28 (12), 1394-1409 (2015).
  8. Goldenberg, R. L., Culhane, J. F., Iams, J. D., Romero, R. Epidemiology and causes of preterm birth. Lancet. 371 (9606), 75-84 (2008).
  9. Erdemir, G., et al. Histological chorioamnionitis: effects on premature delivery and neonatal prognosis. Pediatrics and Neonatology. 54 (4), 267-274 (2013).
  10. Metcalfe, A., Lisonkova, S., Sabr, Y., Stritzke, A., Joseph, K. S. Neonatal respiratory morbidity following exposure to chorioamnionitis. BMC Pediatrics. 17 (1), 128 (2017).
  11. Anblagan, D., et al. Association between preterm brain injury and exposure to chorioamnionitis during fetal life. Scientific Reports. 6, 37932 (2016).
  12. Villamor-Martinez, E., et al. Corrigendum: Chorioamnionitis Is a Risk Factor for Intraventricular Hemorrhage in Preterm Infants: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 10, 102 (2019).
  13. Villamor-Martinez, E., et al. Chorioamnionitis as a risk factor for retinopathy of prematurity: An updated systematic review and meta-analysis. PLoS One. 13 (10), 0205838 (2018).
  14. Randis, T. M., et al. Incidence of early-onset sepsis in infants born to women with clinical chorioamnionitis. Journal of Perinatal Medicine. 46 (8), 926-933 (2018).
  15. Rodrigo, F. G. M., Henriquez F, G. G., Aloy, F. J., Perez, G. A. A. Outcomes of very-low-birth-weight infants exposed to maternal clinical chorioamnionitis: a multicentre study. Neonatology. 106 (3), 229-234 (2014).
  16. Been, J. V., Lievense, S., Zimmermann, L. J., Kramer, B. W., Wolfs, T. G. Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review and meta-analysis. Journal of Pediatrics. 162 (2), 236-242 (2013).
  17. Tanner, S. M., et al. Pathogenesis of necrotizing enterocolitis: modeling the innate immune response. American Journal of Pathology. 185 (1), 4-16 (2015).
  18. Fitzgibbons, S. C., et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. Journal of Pediatric Surgery. 44 (6), 1075-1076 (2009).
  19. Vongbhavit, K., Underwood, M. A. Prevention of Necrotizing Enterocolitis Through Manipulation of the Intestinal Microbiota of the Premature Infant. Clinical Therapeutics. 38 (4), 716-732 (2016).
  20. Yee, W. H., et al. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics. 129 (2), 298-304 (2012).
  21. Gantert, M., et al. Chorioamnionitis: a multiorgan disease of the fetus. Journal of Perinatology. 30, 21-30 (2010).
  22. Hudalla, H., et al. LPS-induced maternal inflammation promotes fetal leukocyte recruitment and prenatal organ infiltration in mice. Pediatric Research. 84 (5), 757-764 (2018).
  23. Yamada, N., et al. Histological severity of fetal inflammation is useful in predicting neonatal outcome. Placenta. 36 (12), 1490-1493 (2015).
  24. Wolfe, K. B., et al. Modulation of lipopolysaccharide-induced chorioamnionitis in fetal sheep by maternal betamethasone. Reproductive Sciences. 20 (12), 1447-1454 (2013).
  25. Normann, E., et al. A novel mouse model of Ureaplasma-induced perinatal inflammation: effects on lung and brain injury. Pediatric Research. 65 (4), 430-436 (2009).
  26. Burd, I., Brown, A., Gonzalez, J. M., Chai, J., Elovitz, M. A. A mouse model of term chorioamnionitis: unraveling causes of adverse neurological outcomes. Reproductive Sciences. 18 (9), 900-907 (2011).
  27. Dell'Ovo, V., et al. An animal model for chorioamnionitis at term. American Journal of Obstetrics and Gynecology. 213 (3), 387 (2015).
  28. Randis, T. M., et al. Group B Streptococcus beta-hemolysin/cytolysin breaches maternal-fetal barriers to cause preterm birth and intrauterine fetal demise in vivo. Journal of Infectious Diseases. 210 (2), 265-273 (2014).
  29. Breen, K., et al. TLR-4-dependent and -independent mechanisms of fetal brain injury in the setting of preterm birth. Reproductive Sciences. 19 (8), 839-850 (2012).
  30. Burd, I., Balakrishnan, B., Kannan, S. Models of fetal brain injury, intrauterine inflammation, and preterm birth. American Journal of Reproductive Immunology. 67 (4), 287-294 (2012).
  31. Agrawal, V., et al. Role of Notch signaling during lipopolysaccharide-induced preterm labor. Journal of Leukocyte Biology. 100 (2), 261-274 (2016).
  32. Filipovich, Y., Klein, J., Zhou, Y., Hirsch, E. Maternal and fetal roles in bacterially induced preterm labor in the mouse. American Journal of Obstetrics and Gynecology. 214 (3), 381-389 (2016).
  33. Alexander, C., Rietschel, E. T. Bacterial lipopolysaccharides and innate immunity. Journal of Endotoxin Research. 7 (3), 167-202 (2001).
  34. McCarthy, R., et al. Mouse models of preterm birth: suggested assessment and reporting guidelines. Biology of Reproduction. 99 (5), 922-937 (2018).
  35. Rueda, C. M., et al. Lipopolysaccharide-Induced Chorioamnionitis Promotes IL-1-Dependent Inflammatory FOXP3+ CD4+ T Cells in the Fetal Rhesus Macaque. Journal of Immunology. 196 (9), 3706-3715 (2016).
  36. Gavilanes, A. W., et al. Chorioamnionitis induced by intraamniotic lipopolysaccharide resulted in an interval-dependent increase in central nervous system injury in the fetal sheep. American Journal of Obstetrics and Gynecology. 200 (4), 431-438 (2009).
  37. Boksa, P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain, Behavior, and Immunity. 24 (6), 881-897 (2010).
  38. Knuesel, I., et al. Maternal immune activation and abnormal brain development across CNS disorders. Nature Reviews Neurology. 10 (11), 643-660 (2014).
  39. Garay, P. A., Hsiao, E. Y., Patterson, P. H., McAllister, A. K. Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain, Behavior, and Immunity. 31, 54-68 (2013).
  40. Smith, S. E., Li, J., Garbett, K., Mirnics, K., Patterson, P. H. Maternal immune activation alters fetal brain development through interleukin-6. Journal of Neuroscience. 27 (40), 10695-10702 (2007).
  41. Elgin, T. G., et al. Fetal exposure to maternal inflammation interrupts murine intestinal development and increases susceptibility to neonatal intestinal injury. Disease Models & Mechanisms. 12 (10), (2019).
  42. Fricke, E. M., et al. Lipopolysaccharide-induced maternal inflammation induces direct placental injury without alteration in placental blood flow and induces a secondary fetal intestinal injury that persists into adulthood. American Journal of Reproductive Immunology. 79 (5), 12816 (2018).
  43. Wynn, J. L., et al. Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18. Proceedings of the National Academy of Sciences of the United States of America. 113 (19), 2627-2635 (2016).
  44. Brown, K. S., et al. Tumor necrosis factor induces developmental stage-dependent structural changes in the immature small intestine. Mediators of Inflammation. 2014, 852378 (2014).
  45. McElroy, S. J., et al. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing enterocolitis. American Journal of Pathology. 184 (10), 2768-2778 (2014).
  46. McElroy, S. J., et al. Tumor necrosis factor receptor 1-dependent depletion of mucus in immature small intestine: a potential role in neonatal necrotizing enterocolitis. American Journal of Physiology - Gastrointestinal and Liver Physiology. 301 (4), 656 (2011).
  47. Stanford, A. H., et al. A direct comparison of mouse and human intestinal development using epithelial gene expression patterns. Pediatric Research. , (2019).
  48. McElroy, S. J., Weitkamp, J. H. Innate Immunity in the Small Intestine of the Preterm Infant. NeoReviews. 12 (9), 517-526 (2011).
  49. McElroy, S. J., Underwood, M. A., Sherman, M. P. Paneth cells and necrotizing enterocolitis: a novel hypothesis for disease pathogenesis. Neonatology. 103 (1), 10-20 (2013).
  50. Park, B. S., Lee, J. O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Experimental & Molecular Medicine. 45, 66 (2013).
  51. Lester, S. N., Li, K. Toll-like receptors in antiviral innate immunity. Journal of Molecular Biology. 426 (6), 1246-1264 (2014).
  52. Pott, J., et al. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLOS Pathogens. 8 (5), 1002670 (2012).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Murine ModelFetal ExposureMaternal InflammationChorioamnionitisNewborn Intestinal DevelopmentNecrotizing EnterocolitisFEMI ProtocolLPS InjectionGestation Day E15Negative Pressure InjectionVaginal Delivery E20Postnatal Day 14RNA QuantificationParaffin embedded Tissue

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved